JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Jun 22, 2026
JNJ — 14 winsPFE — 9 wins
Price Performance
JNJ +50.93%PFE +4.91%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | +0.06% | -1.52% |
| 3 Months | -3.28% | -8.01% |
| 6 Months | +9.80% | -1.23% |
| YTD | +11.05% | +1.27% |
| 1 Year | +50.82% | +5.06% |
| 3 Year | +29.43% | -37.56% |
| 5 Year | +53.52% | -30.92% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +10.2% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | +0.1% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 26.57 | 19.25 |
| Forward P/E | 11.17 | 9.08 |
| PEG Ratio | 2.75 | -3.95 |
| P/S Ratio | 6.02 | 2.36 |
| P/B Ratio | 7.14 | 1.66 |
| EV/EBITDA | 17.41 | 12.33 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $8.65 | $1.31 |
| Gross Margin | +71.49% | +67.26% |
| Operating Margin | +26.58% | +27.90% |
| Net Margin | +21.76% | +18.60% |
| ROE | +25.92% | +8.31% |
| ROA | +10.47% | +3.61% |
| Debt/Equity | 0.22 | 0.72 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.91% | +5.37% |
| Revenue Growth QoQ | -2.04% | -17.69% |
| EPS Growth YoY | -52.86% | -9.55% |
| EPS Growth QoQ | +1.90% | +262.07% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 48.10 | 37.35 |
| % From 20-Day SMA | -0.82% | -2.45% |
| % From 50-Day SMA | -0.24% | -3.92% |
| % From 200-Day SMA | +6.53% | -2.56% |
| % From 52-Week High | -8.70% | -12.28% |
| % From 52-Week Low | +54.20% | +9.11% |
Analyst Ratings
JNJ
Buy(24 analysts)
Strong SellHoldStrong Buy
Price Target
$251.55
+9.46% upside
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$26.75
+6.09% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $579.83B | $149.38B |
| Shares Outstanding | 2.41B | 5.70B |
| Avg Volume (10D) | 8.91M | 44.12M |
| Dividend Yield | 2.18% | 6.56% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, JNJ leads in 14 categories while PFE leads in 9. JNJ has a consensus analyst rating with 24 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +50.82% compared to PFE's +5.06%. In the short term (1 month), JNJ returned +0.06% vs PFE's -1.52%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 26.57 compared to PFE's 19.25. On a price-to-sales basis, JNJ trades at 6.02x vs PFE's 2.36x. Forward P/E: JNJ at 11.17 vs PFE at 9.08.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.91% year-over-year compared to PFE's +5.37%. EPS growth: JNJ at -52.86% vs PFE at -9.55%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 2.18%. PFE pays a dividend with a yield of 6.56%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 24 analysts with a target price of $251.55 (+9.46% upside). PFE has 12 analysts with a target of $26.75 (+6.09% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.